Blueprint Medicines Q1 2025 Update
| Field | Detail |
|---|---|
| Company | Blueprint Medicines Corp |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, pharmaceuticals
TL;DR
Blueprint Medicines filed its Q1 2025 10-Q, showing financial and operational details for the period ending March 31.
AI Summary
Blueprint Medicines Corporation reported its first quarter 2025 results, ending March 31, 2025. The company's filing details its financial position and operational activities for the period. Specific financial figures and operational metrics are presented within the report, reflecting the company's performance in the pharmaceutical preparations sector.
Why It Matters
This filing provides insight into Blueprint Medicines' financial health and operational progress in the first quarter of 2025, which can influence investor decisions and market perception.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Blueprint Medicines faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 46,500,000 — P3Y (Likely represents a financial figure or metric, possibly related to a specific accounting item or valuation, though the exact meaning requires further context from the full filing.)
Key Players & Entities
- Blueprint Medicines Corp (company) — Filer
- 20250331 (date) — Reporting period end date
- 20250501 (date) — Filing date
- 45 Sidney Street, Cambridge, MA 02139 (address) — Company business and mailing address
- 617-374-7580 (phone_number) — Company business phone number
FAQ
What were Blueprint Medicines' total revenues for the quarter ended March 31, 2025?
The provided excerpt does not contain specific revenue figures for the quarter ended March 31, 2025. Further details would be in the full financial statements.
What is the company's primary SIC code?
The company's Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
When is Blueprint Medicines' fiscal year end?
Blueprint Medicines' fiscal year ends on December 31.
What is the filing date of this 10-Q report?
This 10-Q report was filed on May 1, 2025.
What is the reporting period for this 10-Q?
The conforming period of the report is March 31, 2025.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding Blueprint Medicines Corp.